These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23670789)

  • 21. Effects of Quinidine or Rifampin Co-administration on the Single-Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants.
    Rask-Madsen C; Katragadda S; Li M; Ucpinar S; Chinn L; Arora P; Smith P
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):590-600. PubMed ID: 38623935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
    Gandelman K; Zhu T; Fahmi OA; Glue P; Lian K; Obach RS; Damle B
    J Clin Pharmacol; 2011 Feb; 51(2):229-36. PubMed ID: 20371736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Panebianco D; Cote J; Bergman AJ; Van Hoydonck P; Laethem T; Van Dyck K; Chen J; Chavez-Eng C; Archer L; Lutz R; Hilliard D; Snyder K; Jin B; Van Bortel L; Lasseter KC; Al-Huniti N; Dykstra K; Gottesdiener K; Wagner JA
    Br J Clin Pharmacol; 2009 Oct; 68(4):535-45. PubMed ID: 19843057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.
    Borghi C; Cicero AF
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):205-209. PubMed ID: 27852117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
    Chiou WJ; de Morais SM; Kikuchi R; Voorman RL; Li X; Bow DA
    Xenobiotica; 2014 Mar; 44(3):276-82. PubMed ID: 23886114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
    Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
    Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
    Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
    Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
    Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
    Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
    Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
    Clin Pharmacol Ther; 2016 Feb; 99(2):224-34. PubMed ID: 26259716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
    Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The drug-drug interaction potential of rifampicin.
    Srinivas NR
    Clin Ther; 2008 Oct; 30(10):1932-3. PubMed ID: 19014849
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
    Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
    J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.
    Kim JW; Yi S; Kim TE; Lim KS; Yoon SH; Cho JY; Lee MG; Song IS; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2013 Jan; 53(1):75-81. PubMed ID: 23400746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
    Krishna R; Gheyas F; Corr C; Cote J; Liu Y; Wagner J; Gutstein DE
    J Clin Pharmacol; 2018 Dec; 58(12):1578-1585. PubMed ID: 30029292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.